These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27233268)

  • 81. Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.
    Jin J; Liss NM; Chen DH; Liao M; Fox JM; Shimak RM; Fong RH; Chafets D; Bakkour S; Keating S; Fomin ME; Muench MO; Sherman MB; Doranz BJ; Diamond MS; Simmons G
    Cell Rep; 2015 Dec; 13(11):2553-2564. PubMed ID: 26686638
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Discovery of a novel antiviral agent targeting the nonstructural protein 4 (nsP4) of chikungunya virus.
    Wada Y; Orba Y; Sasaki M; Kobayashi S; Carr MJ; Nobori H; Sato A; Hall WW; Sawa H
    Virology; 2017 May; 505():102-112. PubMed ID: 28236746
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Generation of Mouse Monoclonal Antibodies Specific to Chikungunya Virus Using ClonaCell-HY Hybridoma Cloning Kit.
    Yew CW; Tan YJ
    Methods Mol Biol; 2016; 1426():225-33. PubMed ID: 27233275
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Expression and Purification of E2 Glycoprotein from Insect Cells (Sf9) for Use in Serology.
    Chua CL; Sam IC; Chan YF
    Methods Mol Biol; 2016; 1426():51-61. PubMed ID: 27233260
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Development of a micro-neutralization test for chikungunya virus.
    Raharjo E; Tadano M; Okamoto Y; Okuno Y
    Biken J; 1986 Mar; 29(1):27-30. PubMed ID: 3022710
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Dysregulated TGF-β Production Underlies the Age-Related Vulnerability to Chikungunya Virus.
    Uhrlaub JL; Pulko V; DeFilippis VR; Broeckel R; Streblow DN; Coleman GD; Park BS; Lindo JF; Vickers I; Anzinger JJ; Nikolich-Žugich J
    PLoS Pathog; 2016 Oct; 12(10):e1005891. PubMed ID: 27736984
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Development of in-house serological methods for diagnosis and surveillance of chikungunya.
    Galo SS; González K; Téllez Y; García N; Pérez L; Gresh L; Harris E; Balmaseda Á
    Rev Panam Salud Publica; 2017 Aug; 41():e56. PubMed ID: 28902269
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission.
    Porta J; Mangala Prasad V; Wang CI; Akahata W; Ng LF; Rossmann MG
    J Virol; 2016 Feb; 90(3):1169-77. PubMed ID: 26537684
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Detection of chikungunya virus antigen in Aedes albopictus mosquitoes by enzyme-linked immunosorbent assay.
    Konishi E; Takahashi J
    J Virol Methods; 1985 Dec; 12(3-4):279-85. PubMed ID: 3833871
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Infectious Viral Quantification of Chikungunya Virus-Virus Plaque Assay.
    Kaur P; Lee RC; Chu JJ
    Methods Mol Biol; 2016; 1426():93-103. PubMed ID: 27233264
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Characterization of chikungunya virus-like particles.
    Noranate N; Takeda N; Chetanachan P; Sittisaman P; A-Nuegoonpipat A; Anantapreecha S
    PLoS One; 2014; 9(9):e108169. PubMed ID: 25265335
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Fighting back against chikungunya.
    Rudd PA; Mahalingam S
    Lancet Infect Dis; 2015 May; 15(5):488-9. PubMed ID: 25739877
    [No Abstract]   [Full Text] [Related]  

  • 93. Development of 2, 7-Diamino-1, 8-Naphthyridine (DANP) Anchored Hairpin Primers for RT-PCR Detection of Chikungunya Virus Infection.
    Chen H; Parimelalagan M; Takei F; Hapuarachchi HC; Koay ES; Ng LC; Ho PS; Nakatani K; Chu JJ
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004887. PubMed ID: 27571201
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Image Gallery: Flagellate bullous exanthem in chikungunya.
    Vinay K; Saikia UN; Dogra S
    Br J Dermatol; 2017 Oct; 177(4):e162. PubMed ID: 29052889
    [No Abstract]   [Full Text] [Related]  

  • 95. Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells.
    Ruiz Silva M; van der Ende-Metselaar H; Mulder HL; Smit JM; Rodenhuis-Zybert IA
    Sci Rep; 2016 Aug; 6():32288. PubMed ID: 27558873
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Chikungunya Virus Infections Among Infants-Who Classification Not Applicable.
    van Keulen V; Huibers M; Manshande M; van Hensbroek MB; van Rooij L
    Pediatr Infect Dis J; 2018 Mar; 37(3):e83-e86. PubMed ID: 29135829
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Blocking the Exit: CHIKV Neutralizing Antibodies Nip Viral Egress in the Bud.
    McCarthy MK; Morrison TE
    Cell Host Microbe; 2018 Sep; 24(3):328-330. PubMed ID: 30212644
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Evaluation of three commercially-available chikungunya virus immunoglobulin G immunoassays.
    De Salazar PM; Valadere AM; Goodman CH; Johnson BW
    Rev Panam Salud Publica; 2017 Aug; 41():e62. PubMed ID: 28902275
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A Real-Time Cell Analyzing Assay for Identification of Novel Antiviral Compounds against Chikungunya Virus.
    Zandi K
    Methods Mol Biol; 2016; 1426():255-62. PubMed ID: 27233278
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Defining a correlate of protection for chikungunya virus vaccines.
    Milligan GN; Schnierle BS; McAuley AJ; Beasley DWC
    Vaccine; 2019 Nov; 37(50):7427-7436. PubMed ID: 30448337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.